Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

Stevens Capital Management LP made a calculated move by scooping up 6,849 shares of Amgen during Q4, totaling roughly $1.78 ...

According to Benzinga Pro, Amgen's peer group average for short interest as a percentage of float is 5.85%, which means the ...

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Shares of Amgen Inc. AMGN shed 2.39% to $306.86 Tuesday, on what proved to be an all-around favorable trading session for the ...